Option Care Health (NASDAQ:OPCH) Releases FY 2025 Earnings Guidance

Option Care Health (NASDAQ:OPCH) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.610-1.700 for the period, compared to the consensus estimate of 1.630. The company issued revenue guidance of $5.4 billion-$5.6 billion, compared to the consensus revenue estimate of $5.4 billion.

Option Care Health Stock Performance

Shares of OPCH opened at $32.97 on Tuesday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.32 and a current ratio of 1.73. Option Care Health has a twelve month low of $21.39 and a twelve month high of $35.53. The firm’s 50 day moving average price is $33.37 and its two-hundred day moving average price is $28.78. The firm has a market cap of $5.42 billion, a P/E ratio of 27.71, a PEG ratio of 2.30 and a beta of 1.07.

Option Care Health (NASDAQ:OPCH) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.36 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.36. Option Care Health had a net margin of 4.37% and a return on equity of 15.30%. On average, analysts forecast that Option Care Health will post 1.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on OPCH shares. Bank of America upgraded shares of Option Care Health from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $26.00 to $33.00 in a report on Monday, January 13th. Jefferies Financial Group upgraded shares of Option Care Health from a “hold” rating to a “buy” rating and lifted their price objective for the company from $26.00 to $35.00 in a report on Thursday, January 23rd. Barrington Research reiterated an “outperform” rating and issued a $38.00 price objective on shares of Option Care Health in a report on Monday, April 21st. JMP Securities restated a “market outperform” rating and set a $36.00 target price on shares of Option Care Health in a report on Tuesday, April 22nd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Option Care Health from $40.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, March 6th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.75.

Insiders Place Their Bets

In other Option Care Health news, insider Michael Bavaro sold 30,996 shares of the firm’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the completion of the sale, the insider now directly owns 44,974 shares in the company, valued at $1,495,835.24. This trade represents a 40.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.64% of the company’s stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.